α-Synuclein fibrillation products trigger the release of hexokinase I from mitochondria: Protection by curcumin, and possible role in pathogenesis of Parkinson's disease

Extensive research has shown that assembling of α-synuclein amyloid aggregates on mitochondria is an important mechanistic feature of Parkinson's disease (PD) and other Lewy body disorders. However, the molecular mechanism(s) of its neuronal toxicity remain unclear. Type 1 Hexokinase (HKI), a k...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochimica et biophysica acta. Biomembranes 2020-06, Vol.1862 (6), p.183251-183251, Article 183251
Hauptverfasser: Dehghani, Ziba, Meratan, Ali Akbar, Saboury, Ali Akbar, Nemat-Gorgani, Mohsen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 183251
container_issue 6
container_start_page 183251
container_title Biochimica et biophysica acta. Biomembranes
container_volume 1862
creator Dehghani, Ziba
Meratan, Ali Akbar
Saboury, Ali Akbar
Nemat-Gorgani, Mohsen
description Extensive research has shown that assembling of α-synuclein amyloid aggregates on mitochondria is an important mechanistic feature of Parkinson's disease (PD) and other Lewy body disorders. However, the molecular mechanism(s) of its neuronal toxicity remain unclear. Type 1 Hexokinase (HKI), a key enzyme in the control of brain glucose metabolism, plays an important role in protecting against mitochondrially-regulated apoptosis through reducing generation of reactive oxygen species (ROS). The release of mitochondrially-bound HKI causes a significant decrease in enzyme activity and triggers oxidative stress. Here, we have investigated the potency of amyloid fibrillation products arising from α-synuclein and hen egg white lysozyme (HEWL) for the release of HKI and ROS content enhancement in mitochondria isolated from rat brain. Results clearly indicate the capacity of the fibrillation products of α-synuclein, and not HEWL, to trigger release of HKI from the Type A binding site of mitochondria for the enzyme and to induce mitochondrial ROS enhancement in a dose-dependent manner. Moreover, we found that curcumin was very effective in preventing mitochondrial HKI release and ROS enhancement induced by α-synuclein fibrillation products. The pathophysiological significance of mitochondrial HKI activity and localization in pathogenesis of neurodegenerative disorders including PD are discussed. Taken together, these results may offer insight into a possible mechanism by which disease-related peptides and proteins may exert their neuronal toxicity. [Display omitted] •Fibrillation products of α-synuclein trigger release of mitochondrial HKI.•Fibrillation products of HEWL are not able to trigger release of mitochondrial HKI.•Mitochondrial HKI release occurs from Type A, but not Type B, binding site.•Curcumin is very effective in preventing mitochondrial HKI release.•The physicochemical features of amyloid aggregates may influence final cytotoxicity.
doi_str_mv 10.1016/j.bbamem.2020.183251
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2369882285</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0005273620300766</els_id><sourcerecordid>2369882285</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-c966094ada56b64c2784458b8f3bc8904bcf39c363b333c461e35a22c69a11f33</originalsourceid><addsrcrecordid>eNp9Uctu1DAUtRCITgt_gJB3sGgGv-JxWCChCmilSlQC1pbt3Mx4SOzBThDzS93xI_0mHFK6ZHOta52H7jkIvaBkTQmVb_Zra80Aw5oRVr4UZzV9hFZUbZqKScEeoxUhpK7YhssTdJrznhSaYPVTdMIZpVyJZoVu735XX45hcj34gDtvk-97M_oY8CHFdnJjxmPy2y0kPO4AJ-jBZMCxwzv4Fb_7MG9XuEtxwIMfo9vF0CZv3uKbFEdwf6XsEbspuWnw4Ryb0OJDzNnbvujFMorzwYy7uIUA2edZ_Makop1jeJVx6_Ps-Qw96Uyf4fn9e4a-ffzw9eKyuv786eri_XXlBFFj5RopSSNMa2pppXBso4SolVUdt041RFjX8cZxyS3n3AlJgdeGMScbQ2nH-Rl6veiWAH5MkEc9-OygxBIgTlkzLhulGFN1gYoF6lI5KEGnD8kPJh01JXpuSe_10pKeW9JLS4X28t5hsgO0D6R_tRTAuwUA5c6fHpLOzkNw0PpUItVt9P93-AM0kajw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2369882285</pqid></control><display><type>article</type><title>α-Synuclein fibrillation products trigger the release of hexokinase I from mitochondria: Protection by curcumin, and possible role in pathogenesis of Parkinson's disease</title><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Dehghani, Ziba ; Meratan, Ali Akbar ; Saboury, Ali Akbar ; Nemat-Gorgani, Mohsen</creator><creatorcontrib>Dehghani, Ziba ; Meratan, Ali Akbar ; Saboury, Ali Akbar ; Nemat-Gorgani, Mohsen</creatorcontrib><description>Extensive research has shown that assembling of α-synuclein amyloid aggregates on mitochondria is an important mechanistic feature of Parkinson's disease (PD) and other Lewy body disorders. However, the molecular mechanism(s) of its neuronal toxicity remain unclear. Type 1 Hexokinase (HKI), a key enzyme in the control of brain glucose metabolism, plays an important role in protecting against mitochondrially-regulated apoptosis through reducing generation of reactive oxygen species (ROS). The release of mitochondrially-bound HKI causes a significant decrease in enzyme activity and triggers oxidative stress. Here, we have investigated the potency of amyloid fibrillation products arising from α-synuclein and hen egg white lysozyme (HEWL) for the release of HKI and ROS content enhancement in mitochondria isolated from rat brain. Results clearly indicate the capacity of the fibrillation products of α-synuclein, and not HEWL, to trigger release of HKI from the Type A binding site of mitochondria for the enzyme and to induce mitochondrial ROS enhancement in a dose-dependent manner. Moreover, we found that curcumin was very effective in preventing mitochondrial HKI release and ROS enhancement induced by α-synuclein fibrillation products. The pathophysiological significance of mitochondrial HKI activity and localization in pathogenesis of neurodegenerative disorders including PD are discussed. Taken together, these results may offer insight into a possible mechanism by which disease-related peptides and proteins may exert their neuronal toxicity. [Display omitted] •Fibrillation products of α-synuclein trigger release of mitochondrial HKI.•Fibrillation products of HEWL are not able to trigger release of mitochondrial HKI.•Mitochondrial HKI release occurs from Type A, but not Type B, binding site.•Curcumin is very effective in preventing mitochondrial HKI release.•The physicochemical features of amyloid aggregates may influence final cytotoxicity.</description><identifier>ISSN: 0005-2736</identifier><identifier>EISSN: 1879-2642</identifier><identifier>DOI: 10.1016/j.bbamem.2020.183251</identifier><identifier>PMID: 32113849</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Alpha-synuclein ; Curcumin ; Fibrillation products ; HEWL ; Mitochondrial hexokinase I ; Mitochondrial ROS</subject><ispartof>Biochimica et biophysica acta. Biomembranes, 2020-06, Vol.1862 (6), p.183251-183251, Article 183251</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-c966094ada56b64c2784458b8f3bc8904bcf39c363b333c461e35a22c69a11f33</citedby><cites>FETCH-LOGICAL-c408t-c966094ada56b64c2784458b8f3bc8904bcf39c363b333c461e35a22c69a11f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0005273620300766$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32113849$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dehghani, Ziba</creatorcontrib><creatorcontrib>Meratan, Ali Akbar</creatorcontrib><creatorcontrib>Saboury, Ali Akbar</creatorcontrib><creatorcontrib>Nemat-Gorgani, Mohsen</creatorcontrib><title>α-Synuclein fibrillation products trigger the release of hexokinase I from mitochondria: Protection by curcumin, and possible role in pathogenesis of Parkinson's disease</title><title>Biochimica et biophysica acta. Biomembranes</title><addtitle>Biochim Biophys Acta Biomembr</addtitle><description>Extensive research has shown that assembling of α-synuclein amyloid aggregates on mitochondria is an important mechanistic feature of Parkinson's disease (PD) and other Lewy body disorders. However, the molecular mechanism(s) of its neuronal toxicity remain unclear. Type 1 Hexokinase (HKI), a key enzyme in the control of brain glucose metabolism, plays an important role in protecting against mitochondrially-regulated apoptosis through reducing generation of reactive oxygen species (ROS). The release of mitochondrially-bound HKI causes a significant decrease in enzyme activity and triggers oxidative stress. Here, we have investigated the potency of amyloid fibrillation products arising from α-synuclein and hen egg white lysozyme (HEWL) for the release of HKI and ROS content enhancement in mitochondria isolated from rat brain. Results clearly indicate the capacity of the fibrillation products of α-synuclein, and not HEWL, to trigger release of HKI from the Type A binding site of mitochondria for the enzyme and to induce mitochondrial ROS enhancement in a dose-dependent manner. Moreover, we found that curcumin was very effective in preventing mitochondrial HKI release and ROS enhancement induced by α-synuclein fibrillation products. The pathophysiological significance of mitochondrial HKI activity and localization in pathogenesis of neurodegenerative disorders including PD are discussed. Taken together, these results may offer insight into a possible mechanism by which disease-related peptides and proteins may exert their neuronal toxicity. [Display omitted] •Fibrillation products of α-synuclein trigger release of mitochondrial HKI.•Fibrillation products of HEWL are not able to trigger release of mitochondrial HKI.•Mitochondrial HKI release occurs from Type A, but not Type B, binding site.•Curcumin is very effective in preventing mitochondrial HKI release.•The physicochemical features of amyloid aggregates may influence final cytotoxicity.</description><subject>Alpha-synuclein</subject><subject>Curcumin</subject><subject>Fibrillation products</subject><subject>HEWL</subject><subject>Mitochondrial hexokinase I</subject><subject>Mitochondrial ROS</subject><issn>0005-2736</issn><issn>1879-2642</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9Uctu1DAUtRCITgt_gJB3sGgGv-JxWCChCmilSlQC1pbt3Mx4SOzBThDzS93xI_0mHFK6ZHOta52H7jkIvaBkTQmVb_Zra80Aw5oRVr4UZzV9hFZUbZqKScEeoxUhpK7YhssTdJrznhSaYPVTdMIZpVyJZoVu735XX45hcj34gDtvk-97M_oY8CHFdnJjxmPy2y0kPO4AJ-jBZMCxwzv4Fb_7MG9XuEtxwIMfo9vF0CZv3uKbFEdwf6XsEbspuWnw4Ryb0OJDzNnbvujFMorzwYy7uIUA2edZ_Makop1jeJVx6_Ps-Qw96Uyf4fn9e4a-ffzw9eKyuv786eri_XXlBFFj5RopSSNMa2pppXBso4SolVUdt041RFjX8cZxyS3n3AlJgdeGMScbQ2nH-Rl6veiWAH5MkEc9-OygxBIgTlkzLhulGFN1gYoF6lI5KEGnD8kPJh01JXpuSe_10pKeW9JLS4X28t5hsgO0D6R_tRTAuwUA5c6fHpLOzkNw0PpUItVt9P93-AM0kajw</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Dehghani, Ziba</creator><creator>Meratan, Ali Akbar</creator><creator>Saboury, Ali Akbar</creator><creator>Nemat-Gorgani, Mohsen</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200601</creationdate><title>α-Synuclein fibrillation products trigger the release of hexokinase I from mitochondria: Protection by curcumin, and possible role in pathogenesis of Parkinson's disease</title><author>Dehghani, Ziba ; Meratan, Ali Akbar ; Saboury, Ali Akbar ; Nemat-Gorgani, Mohsen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-c966094ada56b64c2784458b8f3bc8904bcf39c363b333c461e35a22c69a11f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alpha-synuclein</topic><topic>Curcumin</topic><topic>Fibrillation products</topic><topic>HEWL</topic><topic>Mitochondrial hexokinase I</topic><topic>Mitochondrial ROS</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dehghani, Ziba</creatorcontrib><creatorcontrib>Meratan, Ali Akbar</creatorcontrib><creatorcontrib>Saboury, Ali Akbar</creatorcontrib><creatorcontrib>Nemat-Gorgani, Mohsen</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochimica et biophysica acta. Biomembranes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dehghani, Ziba</au><au>Meratan, Ali Akbar</au><au>Saboury, Ali Akbar</au><au>Nemat-Gorgani, Mohsen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>α-Synuclein fibrillation products trigger the release of hexokinase I from mitochondria: Protection by curcumin, and possible role in pathogenesis of Parkinson's disease</atitle><jtitle>Biochimica et biophysica acta. Biomembranes</jtitle><addtitle>Biochim Biophys Acta Biomembr</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>1862</volume><issue>6</issue><spage>183251</spage><epage>183251</epage><pages>183251-183251</pages><artnum>183251</artnum><issn>0005-2736</issn><eissn>1879-2642</eissn><abstract>Extensive research has shown that assembling of α-synuclein amyloid aggregates on mitochondria is an important mechanistic feature of Parkinson's disease (PD) and other Lewy body disorders. However, the molecular mechanism(s) of its neuronal toxicity remain unclear. Type 1 Hexokinase (HKI), a key enzyme in the control of brain glucose metabolism, plays an important role in protecting against mitochondrially-regulated apoptosis through reducing generation of reactive oxygen species (ROS). The release of mitochondrially-bound HKI causes a significant decrease in enzyme activity and triggers oxidative stress. Here, we have investigated the potency of amyloid fibrillation products arising from α-synuclein and hen egg white lysozyme (HEWL) for the release of HKI and ROS content enhancement in mitochondria isolated from rat brain. Results clearly indicate the capacity of the fibrillation products of α-synuclein, and not HEWL, to trigger release of HKI from the Type A binding site of mitochondria for the enzyme and to induce mitochondrial ROS enhancement in a dose-dependent manner. Moreover, we found that curcumin was very effective in preventing mitochondrial HKI release and ROS enhancement induced by α-synuclein fibrillation products. The pathophysiological significance of mitochondrial HKI activity and localization in pathogenesis of neurodegenerative disorders including PD are discussed. Taken together, these results may offer insight into a possible mechanism by which disease-related peptides and proteins may exert their neuronal toxicity. [Display omitted] •Fibrillation products of α-synuclein trigger release of mitochondrial HKI.•Fibrillation products of HEWL are not able to trigger release of mitochondrial HKI.•Mitochondrial HKI release occurs from Type A, but not Type B, binding site.•Curcumin is very effective in preventing mitochondrial HKI release.•The physicochemical features of amyloid aggregates may influence final cytotoxicity.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32113849</pmid><doi>10.1016/j.bbamem.2020.183251</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0005-2736
ispartof Biochimica et biophysica acta. Biomembranes, 2020-06, Vol.1862 (6), p.183251-183251, Article 183251
issn 0005-2736
1879-2642
language eng
recordid cdi_proquest_miscellaneous_2369882285
source Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals
subjects Alpha-synuclein
Curcumin
Fibrillation products
HEWL
Mitochondrial hexokinase I
Mitochondrial ROS
title α-Synuclein fibrillation products trigger the release of hexokinase I from mitochondria: Protection by curcumin, and possible role in pathogenesis of Parkinson's disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T03%3A40%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%CE%B1-Synuclein%20fibrillation%20products%20trigger%20the%20release%20of%20hexokinase%20I%20from%20mitochondria:%20Protection%20by%20curcumin,%20and%20possible%20role%20in%20pathogenesis%20of%20Parkinson's%20disease&rft.jtitle=Biochimica%20et%20biophysica%20acta.%20Biomembranes&rft.au=Dehghani,%20Ziba&rft.date=2020-06-01&rft.volume=1862&rft.issue=6&rft.spage=183251&rft.epage=183251&rft.pages=183251-183251&rft.artnum=183251&rft.issn=0005-2736&rft.eissn=1879-2642&rft_id=info:doi/10.1016/j.bbamem.2020.183251&rft_dat=%3Cproquest_cross%3E2369882285%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2369882285&rft_id=info:pmid/32113849&rft_els_id=S0005273620300766&rfr_iscdi=true